Tekmira Pharmaceuticals announced this week that it has launched a phase I/II clinical trial of its siRNA-based cancer therapy TKM-PLK, focusing on two forms of cancer that were particularly responsive to the drug in a previous study.

During a conference call, Tekmira officials also provided updates on its other research and development efforts — including its Ebola infection treatment TKM-Ebola and efforts to develop its lipid nanoparticles, or LNPs, for subcutaneous siRNA delivery — and broke out the company’s second-quarter financial results.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.

Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.

Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.